Our results demonstrated that compared with low expression of CD163Margin, high expression of CD163Margin was significantly associated with larger tumor size (p = 0.005), lymph node metastasis (p = 0.005), PR status (p = 0.006), and higher Ki67 (p = 0.002), which indicated that CD163Margin might be a predictor of prognosis for breast cancer patients. This evidence concerns the gene MKI67 and breast carcinoma.